Immunotherapy of acute myeloid leukemia

Current Pharmaceutical Biotechnology

Volumn 2, Issue 3, 2001, Pages 209-215

  Frankel, A E ^a   Baer, M R ^a   Hogge, D E ^a   Stuart, R K ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; LEUKEMIA ANTIGEN; VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGRAFT; ANIMAL; ANTIGEN RECOGNITION; ARTICLE; BLAST CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL KILLING; CONDITIONING; CONTROLLED STUDY; DONOR; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESISTANCE; DRUG RESPONSE; DRUG TOXICITY; EVIDENCE BASED MEDICINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFUSION; LEUKEMIA REMISSION; MOLECULAR BIOLOGY; MORTALITY; RELAPSE; SALVAGE THERAPY; T LYMPHOCYTE ACTIVATION; TISSUE CULTURE;

ACUTE DISEASE; ANIMALS; CLINICAL TRIALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID; T-LYMPHOCYTES;

EID: 0034856943     PISSN: 13892010     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389201013378699     Document Type: Article

References (55)

1. Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy
2. Cutting edge: The HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cystein residue as identified by a novel mass spectrometric technique
3. HA-1 and the SMCY-derived peptide FIDSYICQV (H-Y) are immunodominant minor histocompatibility antigens after bone marrow transplantation
4. The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism
5. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens
6. Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells
7. Donor-recipient polymorphism of the proteinase 3 gene: A potential target for T-cell alloresponses to myeloid leukemia
8. WT1: What has the last decade told us?
9. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias
10. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide
11. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1
12. Cytotoxic T lymphocytes (CTL) specific for myeloperoxidase-derived HLA-A2-restricted peptides specifically lyse AML and CML cells
13. Fas-independent and nonapoptotic cytotoxicity mediated by a human CD4+ T-cell clone directed against an acute myelogenous leukemia-associated DEK-CAN fusion peptide
14. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR α present in acute promyelocytic leukemia cells
15. Antileukemic HLA-restricted T-cell clones generated with naturally processed peptides eluted from acute myeloblastic leukemia blasts
16. Dendritic cells from acute myeloid leukemia in complete remission pulsed with autologous leukemic cell lysates induce efficient leukemia-specific cytotoxicity
17. Advances in immunology: The HLA system
18. Antigen-processing machinery breakdown and tumor growth
19. Peptide transport in human lymphoblastoid and tumor cells: Effect of transporter associated with antigen presentation (TAP) polymorphism
20. Effect of costimulation and the microenvironment on antigen presentation by leukemia cells
21. Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: Induction of autologous cytotoxic T lymphocytes against leukemia cells in acute patients
22. Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses
23. Cytokine upregulation of the antigen presenting function of acute myeloid leukemia
24. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells
25. Culture requirements for induction of dendritic cell differentiation in acute myeloid leukemia
26. CD34+ acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells
27. CD80-transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens
28. Human leukemic myeloblasts-autologous dendritic cell fusions stimulate potent anti-tumor T-cell autoreactivity: A pre-clinical model for vaccine therapy in patients with acute myeloid leukemia (AML)
29. Dendritic cells fused with acute myelogenous leukemia (AML) blasts induce activation of antitumor cytotoxic lymphocytes
30. Effects of TGF-β on the immune system: Implications for cancer immunotherapy
31. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines
32. The host-tumor immune conflict: From immunosuppression to resistance and destruction
33. Characterization of an AML-derived immuno-modulatory factor(s) that inhibit T cell activation and the signal transduction pathway involved
34. Acute myeloid leukemia cells induce T cells but not NK cell unresponsiveness--implications for the adoptive immunotherapy of leukemia
35. T cell activation determined by T cell receptor number and tunable thresholds
36. Functional diversity of T lymphocytes due to secretion of different cytokine patterns
37. Lineage commitment in the immune system: The T helper lymphocyte grows up
38. Autoimmune disease induced by dendritic cell immunization against leukemia
39. Acute myeloid leukaemia triggering via CD40 induces leukocyte chemoattraction and cytotoxicity against allogenic or autologous leukemic targets
40. Extramedullary relapse in the so-called 'santuary' sites for chemotherapy after donor lymphocyte infusion
41. Relapse of leukemia and lymphoma after marrow transplant: A review of cases with extramedullary relapse
42. How do cytotoxic lymphocytes kill their targets?
43. Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells
44. Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels
45. Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene
46. Identical-twin bone marrow transplants for leukemia
47. Graft-versus-leukemia reactions after bone marrow transplantation
48. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study
49. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: Advantages of T-cell antibodies with narrow specificities
50. Early prediction of relapse after allogeneic transplant for acute myelogenous leukemia
51. Allogeneic transplantation with non-myeloablative or reduced intensity conditioning: The intensity of the conditioning regimen is related to outcome in patients with active disease but not in those in remission at transplantation
52. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
53. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with donor lymphocyte transfusion-a retrospective analysis of EMBT results
54. Advances in immunology: The immune system (first of two parts)
55. Advances in immunology: The immune system (second of two parts)